Vasopressin receptor antagonists and products and methods related thereto

A substantially enantiomerically pure compound having the structure of Formula (XVII-S), or a pharmaceutically acceptable hydrate, solvate, isotope, or salt thereof:

• wherein:
• X is —(CRxRy)nO(CRxRy)q—, —(CRxRy)nS(O)t(CRxRy)q—, —(CRxRy)nN(Rx)(CRxRy)q—, or —(CRxRy)n—,
• Rx is, at each occurrence, independently H, lower alkyl, lower haloalkyl, halo, or R6;
• Ry is, at each occurrence, independently H, —OH, lower alkyl, lower alkoxy, or halo;
• Q1 is N or CR1a, Q2 is N or CR1b, and Q3 is N or CR1c, wherein at least one Q1, Q2, or Q3 is not N;
• R1a, R1b, and R1c are each, independently, H, lower alkyl, lower haloalkyl, lower alkoxy, cyano, or halo;
• R2a and R2b are each, independently, H, lower alkyl, lower haloalkyl, or lower alkoxy;
• R3 is —(CHRz)m-Q-(R4)p, —S(═O)2R5, or —C(═O)R5;
• Rz is H or CH3
• Q is aryl or heteroaryl;
• R4 is, at each occurrence, independently H, —OH, ═O, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, halo, or cyano;
• R5 is H, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, aryl, heteroaryl, cycloalkylalkyl, heterocyclyl, or —O-heterocyclyl;
• R6 is cycloalkyl, heterocyclyl, or —C(═O)R7;
• R7 is H, lower alkyl, or lower haloalkyl;
• n is 0, 1, or 2;
• q is 0, 1, or 2;
• t is 0, 1, or 2;
• m is 0, 1, 2, 3, 4, 5, or 6;
• and
• p is 0, 1, or 2.

A substantially enantiomerically pure compound having the structure of Formula (XVII-R), or a pharmaceutically acceptable hydrate, solvate, isotope, or salt thereof:

• wherein:
• X is —(CRxRy)nO(CRxRy)q—, —(CRxRy)nS(O)t(CRxRy)q—, —(CRxRy)nN(Rx)(CRxRy)q—, or —(CRxRy)n—,
• Rx is, at each occurrence, independently H, lower alkyl, lower haloalkyl, halo, or R6;
• Ry is, at each occurrence, independently H, —OH, lower alkyl, lower alkoxy, or halo;
• Q1 is N or CR1a, Q2 is N or CR1b, and Q3 is N or CR1c, wherein at least one Q1, Q2, or Q3 is not N;
• R1a, R1b, and R1c are each, independently, H, lower alkyl, lower haloalkyl, lower alkoxy, cyano, or halo;
• R2a and R2b are each, independently, H, lower alkyl, lower haloalkyl, or lower alkoxy;
• R3 is —(CHRz)m-Q-(R4)p, —S(═O)2R5, or —C(═O)R5;
• Rz is H or CH3
• Q is aryl or heteroaryl;
• R4 is, at each occurrence, independently H, —OH, ═O, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, halo, or cyano;
• R5 is H, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, aryl, heteroaryl, cycloalkylalkyl, heterocyclyl, or —O-heterocyclyl;
• R6 is cycloalkyl, heterocyclyl, or —C(═O)R7;
• R7 is H, lower alkyl, or lower haloalkyl;
• n is 0, 1, or 2;
• q is 0, 1, or 2;
• t is 0, 1, or 2;
• m is 0, 1, 2, 3, 4, 5, or 6;
• and
• p is 0, 1, or 2.

A substantially enantiomerically pure compound having the structure of Formula (XVIII-S), or a pharmaceutically acceptable hydrate, solvate, isotope, or salt thereof:

• wherein:
• X is —(CRxRy)nO(CRxRy)q—, —(CRxRy)nS(O)t(CRxRy)q—, —(CRxRy)nN(Rx)(CRxRy)q—, or —(CRxRy)n—,
• Rx is, at each occurrence, independently H, lower alkyl, lower haloalkyl, halo, or R6;
• Ry is, at each occurrence, independently H, —OH, lower alkyl, lower alkoxy, or halo;
• Q1 is N or CR1a, Q2 is N or CR1b, and Q3 is N or CR1c, wherein at least one Q1, Q2, or Q3 is not N;
• R1a, R1b, and R1c are each, independently, H, lower alkyl, lower haloalkyl, lower alkoxy, cyano, or halo;
• R2a and R2b are each, independently, H, lower alkyl, lower haloalkyl, or lower alkoxy;
• R3 is —(CHRz)m-Q-(R4)p, —S(═O)2R5, or —C(═O)R5;
• Rz is H or CH3
• Q is aryl or heteroaryl;
• R4 is, at each occurrence, independently H, —OH, ═O, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, halo, or cyano;
• R5 is H, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, aryl, heteroaryl, cycloalkylalkyl, heterocyclyl, or —O-heterocyclyl;
• R6 is cycloalkyl, heterocyclyl, or —C(═O)R7;
• R7 is H, lower alkyl, or lower haloalkyl;
• n is 0, 1, or 2;
• q is 0, 1, or 2;
• t is 0, 1, or 2;
• m is 0, 1, 2, 3, 4, 5, or 6;
• and
• p is 0, 1, or 2.

A substantially enantiomerically pure compound having the structure of Formula (XVIII-R), or a pharmaceutically acceptable hydrate, solvate, isotope, or salt thereof:

• wherein:
• X is —(CRxRy)nO(CRxRy)q—, —(CRxRy)nS(O)t(CRxRy)q—, —(CRxRy)nN(Rx)(CRxRy)q—, or —(CRxRy)n—,
• Rx is, at each occurrence, independently H, lower alkyl, lower haloalkyl, halo, or R6;
• Ry is, at each occurrence, independently H, —OH, lower alkyl, lower alkoxy, or halo;
• Q1 is N or CR1a, Q2 is N or CR1b, and Q3 is N or CR1c, wherein at least one Q1, Q2, or Q3 is not N;
• R1a, R1b, and R1c are each, independently, H, lower alkyl, lower haloalkyl, lower alkoxy, cyano, or halo;
• R2a and R2b are each, independently, H, lower alkyl, lower haloalkyl, or lower alkoxy;
• R3 is —(CHRz)m-Q-(R4)p, —S(═O)2R5, or —C(═O)R5;
• Rz is H or CH3
• Q is aryl or heteroaryl;
• R4 is, at each occurrence, independently H, —OH, ═O, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, halo, or cyano;
• R5 is H, cycloalkyl, lower alkyl, lower haloalkyl, lower alkoxy, aryl, heteroaryl, cycloalkylalkyl, heterocyclyl, or —O-heterocyclyl;
• R6 is cycloalkyl, heterocyclyl, or —C(═O)R7;
• R7 is H, lower alkyl, or lower haloalkyl;
• n is 0, 1, or 2;
• q is 0, 1, or 2;
• t is 0, 1, or 2;
• m is 0, 1, 2, 3, 4, 5, or 6;
• and
• p is 0, 1, or 2.